Strontium ranelate in osteoporosis.

Abstract:

:Strontium ranelate is composed of an organic moiety (ranelic acid) and of two atoms of stable non-radioactive strontium. In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as strontium ranelate enhanced pre-osteoblastic cells replication. The stimulation by strontium ranelate of the replication of osteoprogenitor cells and collagen as well as non-collagenic protein synthesis in osteoblasts provides substantial evidence to categorise SR ranelate as a bone forming agent. In the mouse calvaria culture system, SR ranelate induces a dose-dependent inhibition of labelled calcium release. The inhibitory effects of SR ranelate on bone resorption were close to those of salmon calcitonin. In the isolated rat osteoclast assay, a pre-incubation of bone slices with SR ranelate induced a dose-dependent inhibition of the bone resorbing activity of a treated rat osteoclast. SR ranelate also dose-dependently inhibited, in a chicken bone marrow culture, the expression of both CA II and the alpha-subunit of the vitronectin receptor. These effects showing that SR ranelate significantly affects bone resorption due to direct and/or matrix-mediated inhibition of osteoclast activity and also inhibits osteoclasts differentiation are compatible with the profile of an anti-resorptive drug. In normal rats, administration of SR ranelate induces an improvement in the mechanical properties of the humerus and/or the lumbar vertebra associated with a commensurate increase in bone dimension, shaft and volume. This was not related to any change in the stiffness, suggesting the absence of a mineralisation defect. After oral administration of SR ranelate in humans, the absolute bio-availability of SR ranelate is 27 % after a dose of 2g is given as sachets. The simultaneous intake of SR ranelate and calcium remarkably reduces the bio-availability of SR. SR ranelate was administered in 160 early postmenopausal women, in a 24-month, double-blind, placebo-controlled, prospective randomized study. Daily oral dose of 125 mg, 500 mg, 1 g of SR ranelate were compared to a placebo. At the conclusion of the study, the percent variation of lumbar adjusted BMD from baseline was significantly different in the group receiving 1 g/day of SR as compared to placebo (+ 1.41 % versus 0.98 % respectively). Increase in total hip and neck BMD averages respectively 3.2 % and 2.5 %. SR ranelate does not induce any significant adverse reaction compared to those observed in women receiving a placebo for the same duration. In a phase II study, the effect of SR ranelate in postmenopausal women with vertebral osteoporotic fractures were assessed during a double-blind, placebo-controlled trial. SR ranelate (500 mg, 1 g, 2 g per day) or placebo were given to 353 Caucasian women with prevalent osteoporosis. At the conclusion of this two-year study, the annual increase in lumbar adjusted BMD of the group receiving 2 g of SR ranelate was + 2.97 %. This result was significantly different as compared to placebo. A significant decrease in pyridinium crosslinks (NTX) and an increase in bone specific alkaline phosphatase were evident after 3 and 6 months of treatment. During the second year of treatment, the dose of 2 g was associated with a 4 % reduction in the number of patient experiencing a new vertebral deformity. Bone histomorphometry showed no mineralisation defects. The same percentage of withdrawal following an adverse effect was observed for patients receiving placebo and for those receiving 2 g of strontium ranelate. Currently, strontium ranelate is further investigated in a large Phase III program that includes two extensive trials for the treatment of severe osteoporosis, one assessing SR ranelate effects on the risk of vertebral fractures (SOTI) and one evaluating the effects of SR ranelate on peripheral (non spinal) fractures (TROPOS). The primary analysis of the SOTI study, evaluating the effect of 2 g of strontium ranelate on vertebral fracture rates are expected to be released during the summer 2002.

journal_name

Curr Pharm Des

authors

Reginster JY

doi

10.2174/1381612023393639

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

1907-16

issue

21

eissn

1381-6128

issn

1873-4286

journal_volume

8

pub_type

杂志文章,评审
  • Opioid receptors and their ligands in the musculoskeletal system and relevance for pain control.

    abstract::Interest in opioid drugs like morphine, as the oldest and most potent pain-killing agents known, has been maintained through the years. One of the most frequent chronic pain sensations people experience is associated with pathological conditions of the musculoskeletal system. Chronic musculoskeletal pain is a major he...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/13816128113199990363

    authors: Spetea M

    更新日期:2013-01-01 00:00:00

  • Phytoestrogen genistein and its pharmacological interactions with synthetic endocrine-active compounds.

    abstract::Phytoestrogens are plant-derived compounds with estrogen-like activities. Certain foods such as soy-derived products are known to have high levels of phytoestrogens, and about 25% of commercial infant formulas used in the United States are soy-based. One of the most important phytoestrogens is the isoflavone genistein...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612043383683

    authors: You L

    更新日期:2004-01-01 00:00:00

  • Cell therapy for the treatment of chronic ischemic heart disease.

    abstract::Over the last decade, much was learned about the biology of several types of stem and progenitor cells. It has become apparent that various cell sources may have the capacity to promote cardiomyogenesis and new blood vessel formation through different mechanisms, forming the rationale for cell-based therapy in patient...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211797904172

    authors: Rodrigo SF,Ramshorst Jv,Beeres SL,Bax JJ,Schalij MJ,Atsma DE

    更新日期:2011-10-01 00:00:00

  • Benefits and Limitations of Polymorphic and Amorphous Forms of Active Pharmaceutical Ingredients.

    abstract::Active pharmaceutical ingredients (APIs) can exist in different polymorphic forms as well as in amorphous state. Polymorphic and amorphous forms of APIs can differ in physicochemical properties which in turn can significantly influence their therapeutic safety and effectiveness of the treatment. This review focuses on...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666160804100036

    authors: Talaczynska A,Dzitko J,Cielecka-Piontek J

    更新日期:2016-01-01 00:00:00

  • Developing antiangiogenic peptide drugs for angiogenesis-related diseases.

    abstract::Angiogenesis is regulated by stimulators and inhibitors and involve multiple biological processes including endothelial cell proliferation, migration, cell-cell and cell-matrix adhesion, assembly into tube structures as well as apoptosis. Designing and developing peptides for therapeutic application to inhibit angioge...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161207781039715

    authors: Sulochana KN,Ge R

    更新日期:2007-01-01 00:00:00

  • Hypersensitivity reactions to neuromuscular blocking agents.

    abstract::Neuromuscular blocking agents are the leading drugs responsible for immediate hypersensitivity reactions during anaesthesia. Most hypersensitivity reactions represent IgE-mediated allergic reactions. Their incidence is estimated to be between 1 in 3,000 to 1 in 110,000 general anaesthetics. However striking variations...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208786369704

    authors: Mertes PM,Aimone-Gastin I,Guéant-Rodriguez RM,Mouton-Faivre C,Audibert G,O'Brien J,Frendt D,Brezeanu M,Bouaziz H,Guéant JL

    更新日期:2008-01-01 00:00:00

  • Drug release from ordered mesoporous silicas.

    abstract::The state-of-the-art in the investigation of drugs release from Silica-based ordered Mesoporous Materials (SMMs) is reviewed. First, the SMM systems used like host matrixes are described. Then, the model drugs studied until now, including their pharmacological action, structure and the mesoporous matrix employed for e...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666151106121419

    authors: Doadrio AL,Salinas AJ,Sánchez-Montero JM,Vallet-Regí M

    更新日期:2015-01-01 00:00:00

  • Depression in older persons with mobility limitations.

    abstract::The impact of depression on physical disability is undisputed. There is convincing evidence that depression increases the subsequent risk for physical disability and, in turn, physical disability results in increased depressive symptoms. Moreover, depression affects also the earlier stages of the disablement process (...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/13816128113196660060

    authors: Milaneschi Y,Penninx BW

    更新日期:2014-01-01 00:00:00

  • Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction.

    abstract:BACKGROUND:Fragile X syndrome (FXS) is the most common form of monogenic hereditary cognitive impairment, including intellectual disability, autism, hyperactivity, and epilepsy. METHODS:This article reviews the literature pertaining to the role of synaptic dysfunction in FXS. RESULTS:In FXS, synaptic dysfunction alte...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666191102165206

    authors: Telias M

    更新日期:2019-01-01 00:00:00

  • Reactive oxygen species, inflammation, and lung diseases.

    abstract::Reactive oxygen species (ROS) are well recognized for playing a dual role as both deleterious and beneficial species. ROS are products of normal cellular metabolism and under physiological conditions, participate in maintenance of cellular 'redox homeostasis. Overproduction of ROS, results in oxidative stress. Oxidati...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212802083716

    authors: Rosanna DP,Salvatore C

    更新日期:2012-01-01 00:00:00

  • Compartmentalized and internally structured particles for drug delivery--a review.

    abstract::Recent advances in the fabrication, characterization and application of micro- and nano-particles that possess a non-uniform internal structure are reviewed. The particle structures include core-shell particles, particles with multiple cores or a multi-layered structure, porous particles with both regular and random p...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811319350007

    authors: Čejková J,Štêpánek F

    更新日期:2013-01-01 00:00:00

  • Cingulate volume abnormalities in emerging psychosis.

    abstract:BACKGROUND:Neuroanatomical abnormalities, including cingulate cortex volume abnormalities, are a common feature in psychosis. However, the extent to which these are related to a vulnerability to psychosis, as opposed to the disorder per se, is less certain. AIM UND HYPOTHESES: The aim of the present study is to compare...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161212799316316

    authors: Röthlisberger M,Riecher-Rössler A,Aston J,Fusar-Poli P,Radü EW,Borgwardt S

    更新日期:2012-01-01 00:00:00

  • Current therapeutic strategies and future perspectives for the prevention of arterial thromboembolism: focus on atrial fibrillation.

    abstract::Arterial thromboembolism is a sudden obstruction of arterial blood flow caused by dislodgment of a blood clot from the site of its formation. Atrial fibrillation (AF) is the most common cardiac arrhythmia and a major risk factor for arterial thromboembolism in clinical practice. Most of AF-related arterial thromboembo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210793563400

    authors: Potpara TS,Lip GY

    更新日期:2010-01-01 00:00:00

  • Current Perspectives Regarding Stem Cell-based Therapy for Ischemic Stroke.

    abstract::Stroke is a leading cause of death and disability worldwide. Conventional treatment has a limitation of very narrow therapeutic time window and its devastating nature necessitate a novel regenerative approach. Transplanted stem cells resulted in functional recovery through multiple mechanisms including neuroprotection...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666180604111806

    authors: Kwak KA,Kwon HB,Lee JW,Park YS

    更新日期:2018-01-01 00:00:00

  • Smoking and cardiovascular system: cellular features of the damage.

    abstract::Two morphological features may be seen as a main result of the cardiovascular cell damage caused by cigarette smoking: myocardial cell necrosis and smoke cardiomyopathy that, however, can lead to cell necrosis in case of chronic prolonged exposure to tobacco smoke. Both these pathological patterns recognise hypoxia as...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208784746699

    authors: Leone A,Landini L Jr,Biadi O,Balbarini A

    更新日期:2008-01-01 00:00:00

  • Appreciation of medical treatments through confidence intervals.

    abstract::The typical way of judging about either the efficacy of a new treatment or, on the contrary, the damage of a pollutant agent is through a test of hypothesis having its ineffectiveness as null hypothesis. This is the typical operational field of Kolmogorov's statistical framework where wastes of data (for instance non ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161207780765891

    authors: Apolloni B,Bassis S,Gaito S,Malchiodi D

    更新日期:2007-01-01 00:00:00

  • Mechanisms and risk of chemically induced aneuploidy in mammalian germ cells.

    abstract::Aneuploidy is a pathological condition that affects 35% of human spontaneous abortions and 0.3% of livebirths. In spite of the increasing knowledge about molecular mechanisms of meiosis and chromosome segregation, maternal age remains the only ascertained aetiological factor. Genetically modified mouse models have bee...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206776389859

    authors: Pacchierotti F,Ranaldi R

    更新日期:2006-01-01 00:00:00

  • Hypothetical Role of Growth Factors to Reduce Intervertebral Disc Degeneration Significantly through Trained Biological Transformations.

    abstract:BACKGROUND:From the evidence of failed injection-based growth factor therapies, it has been proposed that a naturally triggered uninterrupted blood circulation of the growth factors would be superior. OBJECTIVE:We seek to stimulate discussions and more research about the possibility of using the already available grow...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666201019104201

    authors: Muresanu C,Somasundaram SG,Vissarionov SV,Gavryushova LV,Nikolenko VN,Mikhaleva LM,Kirkland CE,Aliev G

    更新日期:2020-10-18 00:00:00

  • Improved immunotoxins with novel functional elements.

    abstract::Immunotoxins (ITs) are protein-based drugs combining a target-specific binding domain (usually derived from an antibody) and a cytotoxic domain to kill target cells. They are among the most promising new therapeutic tools to fight cancer, and several clinical trials have been completed with encouraging results. Althou...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209788923930

    authors: Hetzel C,Bachran C,Tur MK,Fuchs H,Stöcker M

    更新日期:2009-01-01 00:00:00

  • Treatment of patients with schizophrenia and substance abuse disorders.

    abstract::Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessme...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612043384114

    authors: Tsuang J,Fong TW

    更新日期:2004-01-01 00:00:00

  • The Inflammation Network in the Pathogenesis of Erectile Dysfunction: Attractive Potential Therapeutic Targets.

    abstract:BACKGROUND:Erectile dysfunction (ED) is an evolving health problem in the aging male population. Chronic low-grade inflammation is a critical component of ED pathogenesis and a probable intermediate stage of endothelial dysfunction, especially in metabolic diseases, with the inclusion of obesity, metabolic syndrome, an...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612826666200424161018

    authors: Kaya-Sezginer E,Gur S

    更新日期:2020-01-01 00:00:00

  • Gene vectors for cytokine expression in vivo.

    abstract::The understanding of cytokine networks and the exploitation of these networks for the treatment of immune and inflammatory diseases as well as cancer depend on in vivo delivery of cytokines. Due to instability of recombinant cytokine proteins, investigators have employed cytokine-encoding gene therapy vectors to induc...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612003400551

    authors: Hitt MM,Gauldie J

    更新日期:2000-04-01 00:00:00

  • Optimization of cardiac metabolism in heart failure.

    abstract::The derangement of the cardiac energy substrate metabolism plays a key role in the pathogenesis of heart failure. The utilization of non-carbohydrate substrates, such as fatty acids, is the predominant metabolic pathway in the normal heart, because this provides the highest energy yield per molecule of substrate metab...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211798357773

    authors: Nagoshi T,Yoshimura M,Rosano GM,Lopaschuk GD,Mochizuki S

    更新日期:2011-12-01 00:00:00

  • Interactive endogenous small molecule (gaseous) signaling: implications for teratogenesis.

    abstract::Dioxygen (O2) is an exogenously supplied gas with a number of properties that make it valuable as a biological source of energy and as a result much of life has become dependent on this molecule. Nitric oxide (NO), carbon dioxide (CO) and hydrogen sulfide (H2S) are small molecules that are sometimes in a gaseous state...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161207782110525

    authors: Fukuto JM,Collins MD

    更新日期:2007-01-01 00:00:00

  • Antibody-mediated endothelial cell damage via nitric oxide.

    abstract::Vascular disorders, resulting from endothelial cell dysfunction, may be caused by various stimuli, including infectious pathogens, cytotoxic reagents, and pathophysiological mechanisms mediated by immune responses. Endothelial cell dysfunction characterized by apoptosis and abnormal immune activation is, at least in p...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612043453469

    authors: Lin YS,Lin CF,Lei HY,Liu HS,Yeh TM,Chen SH,Liu CC

    更新日期:2004-01-01 00:00:00

  • Vitamin D and Sleep Regulation: Is there a Role for Vitamin D?

    abstract:BACKGROUND:Vitamin D exerts multiple pleiotropic effects beyond its role in calcium-phosphate metabolism. Growing evidence suggests an association between hypovitaminosis D and sleep disorders, thus increasing the interest in the role of this vitamin in the regulatory mechanisms of the sleep-wake cycle. OBJECTIVE:The ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666200310145935

    authors: Romano F,Muscogiuri G,Di Benedetto E,Zhukouskaya VV,Barrea L,Savastano S,Colao A,Di Somma C

    更新日期:2020-01-01 00:00:00

  • Recent Advances towards the Treatment of Depressive Disorders.

    abstract:: ...

    journal_title:Current pharmaceutical design

    pub_type: 社论

    doi:10.2174/138161282422181019144120

    authors: Li K,Wang X

    更新日期:2018-01-01 00:00:00

  • Functional domains of aquaporin-1: keys to physiology, and targets for drug discovery.

    abstract::Aquaporins (AQPs) are expressed in physiologically essential tissues and organs in which edema and fluid imbalances are of major concern. Potential roles in brain water homeostasis and edema, angiogenesis, cell migration, development, neuropathological diseases, and cancer suggest that this family of membrane proteins...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161207782341349

    authors: Yool AJ

    更新日期:2007-01-01 00:00:00

  • Recent progress in work on PGD2 antagonists for drugs targeting allergic diseases.

    abstract::Prostaglandin (PG) D(2), the major cyclooxygenase metabolite generated from immunologically stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases due to its various inflammatory effects. However, the lack of PGD(2) (DP) receptor antagonists has limited the study of its essential role...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612043382864

    authors: Mitsumori S

    更新日期:2004-01-01 00:00:00

  • Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome.

    abstract::Increased visceral adiposity, is an emerging cardiovascular risk factor. There is now a compelling need to quantify visceral adipose tissue not only for diagnostic purposes, but also for therapeutic interventions with weight reduction drugs or pharmaceuticals targeted to adipose tissue, as well as anti-obesity medicat...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161207781039670

    authors: Iacobellis G,Sharma AM

    更新日期:2007-01-01 00:00:00